HARMONY BIOSCIENCES HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.32 USD | +1.35% |
|
-0.27% | -9.23% |
| 04-11 | Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy | MT |
| 04-03 | Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms | MT |
| Sales 2024 * | 711M 56.9B | Sales 2025 * | 840M 67.23B | Capitalization | 1.67B 133B |
|---|---|---|---|---|---|
| Net income 2024 * | 180M 14.41B | Net income 2025 * | 247M 19.77B | EV / Sales 2024 * | 1.83 x |
| Net cash position 2024 * | 367M 29.34B | Net cash position 2025 * | 646M 51.71B | EV / Sales 2025 * | 1.21 x |
| P/E ratio 2024 * |
9.94
x | P/E ratio 2025 * |
7.21
x | Employees | 246 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Harmony Biosciences Holdings, Inc.
More recommendations
More press releases
| 1 day | +1.35% | ||
| 1 week | -0.27% | ||
| Current month | -12.69% | ||
| 1 month | -8.43% | ||
| 3 months | -5.66% | ||
| 6 months | +49.82% | ||
| Current year | -9.23% |
1 week
28.14
30.14
1 month
28.1434.08
Current year
28.1435.40
1 year
18.6139.27
3 years
18.6162.09
5 years
18.6162.09
10 years
18.6162.09
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Dayno
CEO | Chief Executive Officer | 66 | 31/10/17 |
| Director of Finance/CFO | 53 | 28/03/21 | |
David Bradshaw
CTO | Chief Tech/Sci/R&D Officer | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeffrey Aronin
FOU | Founder | 56 | 24/07/17 |
R. Graf
BRD | Director/Board Member | 59 | 10/11/20 |
Andreas Wicki
BRD | Director/Board Member | 64 | 31/08/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.52% | 16 M€ | -8.49% | ||
| 0.35% | 29 M€ | -4.33% | ||
| 0.31% | 27 M€ | -5.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 29.32 | +1.35% | 376,165 |
| 25/04/24 | 28.93 | -1.03% | 313,048 |
| 24/04/24 | 29.23 | +1.32% | 374,235 |
| 23/04/24 | 28.85 | -1.70% | 425,156 |
| 22/04/24 | 29.35 | -0.17% | 298,843 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
29.32
USD
Average target price
41.5
USD
Spread / Average Target
+41.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.23% | 1.67B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HRMY Stock
